Ascentage Pharma Group International (Stock Code: 6855) disclosed a further grant of restricted share units (RSUs) under its 2022 RSU Scheme and a grant of share options under its Post-IPO Share Option Scheme.
As of the announcement date, 1,304,457 RSUs were granted to 146 individuals, accounting for around 0.35% of the Company’s total issued share capital. These include grants to directors, senior management, and service providers offering research, development, and clinical trial services. The vesting periods vary, with some awards vesting in equal tranches over a four-year term and others on specific schedules for select individuals. Part of one participant’s RSUs will vest in under 12 months, justified as a performance-based year-end bonus.
The Board approved the RSU grants, subject to performance targets and a clawback mechanism whereby unvested awards lapse under specific circumstances, such as ceasing employment or breaching contractual obligations.
Additionally, 736,607 share options were granted under the Post-IPO Share Option Scheme, representing about 0.20% of the Company’s total issued share capital. These options feature a ten-year exercise period at an exercise price of HK$63.35 per share, with vesting schedules of either monthly tranches over a year or four equal tranches from 2026 to 2029. Certain grants to non-executive and independent non-executive directors use an accelerated vesting schedule under 12 months, deemed appropriate based on their contributions and responsibilities.
The newly issued shares will be satisfied and listed under the mandates approved by shareholders in May 2025, subject to service provider and overall scheme limits. The Board views both the RSU and share option grants as aligned with the Company’s retention and reward strategies, designed to recognize outstanding performance, support long-term growth, and incentivize key individuals and service providers who contribute to research, development, and clinical trials.
Comments